tiprankstipranks
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
US Market

Royalty Pharma (RPRX) Income Statement

Compare
1,248 Followers

Royalty Pharma Income Statement

Last quarter (Q4 2024), Royalty Pharma's total revenue was $594.00M, a decrease of -0.34% from the same quarter last year. In Q4, Royalty Pharma's net income was $208.00M. See Royalty Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 2.26B$ 2.35B$ 2.24B$ 2.29B$ 2.12B
Gross Profit
$ 2.26B$ 1.79B$ 2.23B$ 2.27B$ 2.03B
Operating Expenses
$ 971.00M$ 862.40M$ 1.31B$ 858.75M$ 527.00M
Depreciation and Amortization
$ 0.00$ 395.13M$ 5.67M$ 23.00M$ 23.06M
EBITDA
$ 1.29B$ 1.89B$ 928.56M$ 1.45B$ 1.68B
Operating Income
$ 1.29B$ 1.49B$ 977.50M$ 1.43B$ 1.59B
Other Income/Expenses
$ 39.00M$ 207.94M$ -77.00M$ -189.51M$ 106.56M
Pretax Income
$ 1.33B$ 1.70B$ 230.06M$ 1.24B$ 1.70B
Net Income
$ 859.00M$ 1.13B$ 42.83M$ 478.75M$ 495.20M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ 1.92$ 3.41$ 0.10$ 1.15$ 1.32
Diluted EPS
$ 1.45$ 2.53$ 0.10$ 1.15$ 1.32
Weighted Average Shares Outstanding
447.63M 447.60M 437.96M 414.79M 375.44M
Weighted Average Shares Outstanding (Diluted)
592.73M 602.90M 437.97M 414.80M 375.45M
Currency in USD

Royalty Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis